entertainment -WSS

entertainment

author：fashion 2025-09-30 00:39:33 - browse：3678

An AstraZeneca sign at ESMO in Madrid. — An AstraZeneca ad at ESMO 2023 in Madrid. Andrew Joseph/STAT

MADRID — Questions about one of AstraZeneca’s key cancer drug candidates — and the dribs and drabs that have come out about its performance — have been dogging the company for months.

On Monday, data presented here from a trial of the drug in advanced non-small cell lung cancer provided at least a fuller look. While the results assuaged some of the safety fears that flared when initial information was released over the summer, they only heightened concerns about the drug’s ability to outperform standard chemotherapy — though they perhaps pointed to an opportunity for the drug in a subset of patients.

The trial, detailed here in a prime session at the annual meeting of the European Society for Medical Oncology, is testing a therapy called datopotamab deruxtecan, or Dato-DXd, in advanced or metastatic non-small cell lung cancer in patients who already tried at least first-line treatments. Patients were randomized to either receive chemotherapy or Dato-DXd, which AstraZeneca is developing with Daiichi Sankyo.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The high cost of giving birth even with insurance
Next article： How to pay for weight loss drugs and save Medicare

explore

WSS

Cigna, Humana reportedly in talks to merge

Scientists uncover potential path to treating deadly childhood tumor

Scientists uncover potential path to treating deadly childhood tumor

U.K. decision on ALS drug has neurologists, advocates up in arms

Oral obesity drug from Viking Therapeutics hits key early target

Pediatric cancer treatments threatened by a new FDA policy

knowledge

entertainment

focus

Guidelines to prevent youth baseball injuries need more muscle

Organ aging and disease risk measured by new blood test

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Pancreatic cancer is often deadly, but new discoveries are raising hope

Medical records are filled with copy

30 years of 'Listening to Prozac'

Moonlake's readout produced a cash windfall. Risks remain

Fetal surgery at risk from Dobbs and new abortion restrictions

Moonlake's readout produced a cash windfall. Risks remain

Trial using CRISPR to edit HIV out of cells disappoints

focus

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Pediatric cancer treatments threatened by a new FDA policy

Drug companies' payments and gifts affect physicians' prescribing

Pediatric cancer treatments threatened by a new FDA policy

Overprescribed: High cost isn't America's only drug problem

UnitedHealth has 90,000 doctors — 10% of all physicians in U.S.

leisure time

explore

hotspot

focus